PT  - JOURNAL ARTICLE
AU  - Helen J. Close
AU  - Lucy F. Stead
AU  - Jérémie Nsengimana
AU  - Katrina A. Reilly
AU  - Alastair Droop
AU  - Heiko Wurdak
AU  - Ryan K. Mathew
AU  - Robert Corns
AU  - Julia Newton-Bishop
AU  - Alan A. Melcher
AU  - Susan C. Short
AU  - Graham P. Cook
AU  - Erica B. Wilson
TI  - Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma
AID  - 10.1101/792846
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 792846
4099  - http://biorxiv.org/content/early/2019/10/04/792846.short
4100  - http://biorxiv.org/content/early/2019/10/04/792846.full
AB  - Glioblastoma (GBM) is an aggressive cancer with a very poor prognosis. Generally viewed as weakly immunogenic, GBM responds poorly to current immunotherapies. To better understand this problem we used a combination of NK cell functional assays together with gene and protein expression profiling to define the NK cell response to GBM and explore immunosuppression in the GBM microenvironment. In addition, we used transcriptome data from patient cohorts to classify GBM according to immunological profiles. We show that glioma stem-like cells, a source of post-treatment tumour recurrence, express multiple immunomodulatory cell surface molecules and are targeted in preference to normal neural progenitor cells by natural killer (NK) cells ex vivo. In contrast, GBM-infiltrating NK cells express reduced levels of activation receptors within the tumour microenvironment, with hallmarks of TGF-β mediated inhibition. This NK cell inhibition is accompanied by expression of mutiple immune checkpoint molecules on T cells. Single cell transcriptomics demonstrated that both tumour and haematopoietic-derived cells in GBM express multiple, diverse mediators of immune evasion. Despite this, immunome analysis across a patient cohort identifies a spectrum of immunological activity in GBM, with active immunity marked by co-expression of immune effector molecules and feedback inhibitory mechanisms. Our data show that GBM is recognised by the immune system but that anti-tumour immunity is restrained by multiple immunosuppressive pathways, some of which operate in the healthy brain. The presence of immune activity in a subset of patients suggests that these patients will more likely benefit from combination immunotherapies directed against multiple immunosuppressive pathways.